CWA Asset Management Group LLC Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

CWA Asset Management Group LLC acquired a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 283 shares of the biopharmaceutical company’s stock, valued at approximately $298,000.

Several other hedge funds have also recently modified their holdings of REGN. Stephens Consulting LLC acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at about $26,000. Sachetta LLC increased its holdings in shares of Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 10 shares in the last quarter. Crewe Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at about $28,000. Lynx Investment Advisory acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at about $33,000. Finally, Family Firm Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at about $33,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.6 %

Shares of REGN stock opened at $821.00 on Wednesday. The stock’s fifty day moving average is $1,014.52 and its two-hundred day moving average is $1,037.74. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The firm has a market capitalization of $90.22 billion, a P/E ratio of 20.43, a PEG ratio of 3.13 and a beta of 0.15. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $784.96 and a fifty-two week high of $1,211.20.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. BMO Capital Markets cut their price target on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Leerink Partners reiterated a “market perform” rating and issued a $1,077.00 price target (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. Leerink Partnrs downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Royal Bank of Canada cut their price target on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Finally, JPMorgan Chase & Co. cut their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a report on Thursday, October 24th. One analyst has rated the stock with a sell rating, three have given a hold rating and eighteen have assigned a buy rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $1,107.25.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 7.48% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.